91Even if that conclusion is founded on reasoning which relies on an economic approach based on the observation of the reaction of demand to relative price changes, it is also applicable to the present case and is not invalidated by the specific features, alleged by the applicants, which characterise pharmaceutical product markets, namely, in particular, that prescribing doctors and patients display only limited sensitivity to price changes. Whatever the actual applicability of the theoretical approach set out in paragraph 87 above to pharmaceutical product markets, and without needing to adopt a position in this respect, the Court notes that the assertion that prescribing doctors and patients are not sensitive to relative price changes does not affect the validity of the view that, in principle, the gradual nature of the increase in sales of a new product substituting for an existing product is not sufficient to conclude that the existing product necessarily exercises a significant competitive constraint over the new one.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.